Cargando…

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

BACKGROUND AND AIMS: We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs). APPROACH AND RESULTS: In this pooled analysis of two single‐center, phase Ib cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jun, Sun, Yongkun, Zhang, Wen, Yuan, Jiajia, Peng, Zhi, Wang, Wei, Gong, Jifang, Yang, Lin, Cao, Yanshuo, Zhao, Hong, Chen, Chao, Wang, Weifeng, Shen, Lin, Zhou, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Liver Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970018/ https://www.ncbi.nlm.nih.gov/pubmed/35491432 http://dx.doi.org/10.1002/hep.32548

Ejemplares similares

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial
por: Lan, Chun-Yan, et al.
Publicado: (2022)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Widespread gaps in the quality of care for primary biliary cholangitis in UK
por: Sivakumar, Mathuri, et al.
Publicado: (2021)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
por: Yoo, Changhoon, et al.
Publicado: (2023)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

CT With Hepatic Arterioportography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial
por: Ohki, Takamasa, et al.
Publicado: (2013)

Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list—a case study
por: Hallsworth, Kate, et al.
Publicado: (2016)

Biliary intraepithelial neoplasia: a case with benign biliary stricture
por: Jung, Wonkyung, et al.
Publicado: (2011)

Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI
por: Jiang, Hanyu, et al.
Publicado: (2022)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
por: Park, Joong-Won, et al.
Publicado: (2015)

A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection
por: Klompenhouwer, Anne J., et al.
Publicado: (2020)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence
por: Giordano, Silvia, et al.
Publicado: (2020)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course
por: van Rosmalen, Belle V., et al.
Publicado: (2021)

Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory
por: Li, Chenxi, et al.
Publicado: (2022)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
por: Muñoz‐Martínez, Sergio, et al.
Publicado: (2022)

Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis
por: Costentin, Charlotte E., et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01
por: Jarman, Edward J., et al.
Publicado: (2022)

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)
por: Xie, Lu, et al.
Publicado: (2023)

2450 Delirium and catatonia: Age matters
por: Wilson, Jo E., et al.
Publicado: (2018)

Biliary hamartoma presented as a single mass
por: Shin, Yong Moon
Publicado: (2011)

CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival After Resection of Pancreatic Adenocarcinoma
por: Liao, Wei-Chih, et al.
Publicado: (2012)

The Impact of Biliary Reconstruction Methods on Small Partial Liver Grafts
por: Yoshikawa, Junichi, et al.
Publicado: (2020)

Biliary Strictures Are Associated With Both Early and Late Hepatic Artery Stenosis
por: Hann, Angus, et al.
Publicado: (2020)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Long-term Outcome of Endoscopic and Percutaneous Transhepatic Approaches for Biliary Complications in Liver Transplant Recipients
por: Rönning, Jesper, et al.
Publicado: (2019)

Role of MRCP in Diagnosing Biliary Anastomotic Strictures After Liver Transplantation: A Single Tertiary Care Center Experience
por: Akbar, Ali, et al.
Publicado: (2018)

Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients
por: Pearson, Terra, et al.
Publicado: (2019)

Hilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge
por: Thaker, Sarang, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9puqi5gi8k7adrbi5a5mr5f58c